Close

HUTCHMED (China) (HCM) Announces Agreement with NHSA for Inclusion of ORPATHYS to the National Reimbursement Drug List in China Jan 18, 2023 09:30AM
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China Jan 18, 2023 09:30AM
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in Aug 8, 2022 06:01AM
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations Jun 22, 2021 01:15PM
Edison issues ADR update on Hutchison China MediTech (HCM) Aug 10, 2020 09:10AM


Aug 6, 2020 04:05PM BeiGene Reports Second Quarter 2020 Financial Results
Jul 6, 2020 12:55PM Edison Issues ADR Outlook on Hutchison China MediTech (HCM)
May 26, 2020 02:00AM Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
Apr 22, 2020 08:15AM Edison Issues ADR Update on Hutchison China MediTech (HCM)
Nov 29, 2019 07:37AM Hutchison China MediTech (HCM) announces Elunate have been included in China's National Reimbursement Drug List by NHSA
Nov 29, 2019 07:35AM Edison issues ADR update on Hutchison China MediTech (HCM)
Oct 10, 2019 07:45AM Edison issues ADR update on Hutchison China MediTech (HCM)
Oct 17, 2017 06:27AM Chi-Med (HCM) and AstraZeneca's (AZN) Savolitinib Shows Encouraging Activity in EGFR Mutation-Positive Lung Cancer with MET-Amplification
Oct 17, 2017 02:00AM Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
Jun 29, 2017 03:44AM Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma
Feb 14, 2017 05:16AM Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium
Feb 14, 2017 02:26AM Hutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU
Mar 17, 2016 06:00AM Hutchison China MediTech Limited (Nasdaq: HCM) to Ring The Nasdaq Stock Market Closing Bell in Celebration of IPO